Aciclovir Generis

Quick links to important sections

Aciclovir Generis

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aciclovir Generis

What is Aciclovir Generis?

Aciclovir Generis is a medicinal product containing the active substance aciclovir. It belongs to a group of medicines known as antivirals, which are specifically designed to treat infections caused by certain types of viruses.

Therapeutic Classification and Mechanism

Aciclovir is a synthetic purine nucleoside analogue. Its primary function is to inhibit the replication of specific viruses within the body. When the medication enters a virus-infected cell, it undergoes a chemical transformation that allows it to interfere with the virus's DNA polymerase. By integrating into the viral DNA chain, it acts as a chain terminator, preventing the virus from copying its genetic material and spreading to healthy cells.

Targeted Pathogens

Aciclovir Generis is primarily used to manage infections associated with the herpesviridae family. This includes:

  • Herpes Simplex Virus Type 1 (HSV-1): Commonly associated with oral infections and cold sores.
  • Herpes Simplex Virus Type 2 (HSV-2): Typically associated with genital infections.
  • Varicella-Zoster Virus (VZV): The virus responsible for causing chickenpox and shingles (herpes zoster).

Clinical Applications

The medication is utilized for both the treatment of active outbreaks and the suppression of recurrent infections. By limiting viral multiplication, the medicine helps to reduce the duration of the infection, alleviate symptoms associated with viral shedding, and promote the healing of lesions. In individuals with weakened immune systems, it may also be used as a preventive measure to reduce the risk of initial infection or reactivation of a latent virus.

Regulatory References

  1. MedlinePlus Drug Information on Acyclovir

What side effects are possible with Aciclovir Generis?

Possible Side Effects and Safety Information: Aciclovir Generis

Like all medicines, Aciclovir Generis can cause side effects, although not everybody experiences them. Most side effects are typically mild to moderate and temporary. Patients should be aware of the range of possible reactions and consult a healthcare professional if they are concerned.


Common Side Effects

These effects occur in more than 1 in 100 people and may include:

  • Gastrointestinal issues: Nausea, vomiting, diarrhea, and abdominal pain.
  • Nervous system: Headache and dizziness.
  • Skin: Rashes, itching, and increased sensitivity to sunlight (photosensitivity).

Uncommon and Rare Side Effects

  • Uncommon effects (less than 1 in 100 people): Hives (urticaria), and accelerated diffuse hair loss (the link to Aciclovir is uncertain).
  • Rare effects (less than 1 in 1,000 people): Reversible increases in liver enzymes and bilirubin, and angioedema (swelling beneath the skin).
  • Very rare effects (less than 1 in 10,000 people): Changes in blood counts (such as anemia, leukopenia, and thrombocytopenia), acute kidney failure, and neurological issues (such as agitation, confusion, tremor, hallucinations, and seizures). These severe neurological effects are generally reversible and are often reported in patients with pre-existing kidney impairment or other predisposing factors.

Important Safety Advice

Allergic Reactions: Seek immediate medical attention if you experience signs of a severe allergic reaction (anaphylaxis) such as difficulty breathing, swelling of the face, tongue, or throat, or a widespread rash. This is a rare but serious risk.

Kidney Function: Adequate hydration is essential, especially when taking high doses, to help prevent rare occurrences of kidney problems, including acute renal failure. Patients with existing kidney or nervous system problems, or the elderly, should be carefully monitored as they may be at increased risk of side effects.

Overdose and Emergency Response

Aciclovir Generis Overdose and when to seek help

The official Aciclovir overdose profile, defined by government regulatory authorities, is characterized by specific documented risks and mandatory emergency actions. Overexposure primarily affects the renal system and the central nervous system (CNS).

Element Official Regulatory Statement
Documented presentations Gastrointestinal effects (nausea, vomiting), and neurological signs including confusion, agitation, somnolence, and seizures.
Physiological systems affected Renal system (potential for acute renal failure) and Central Nervous System (CNS) (leading to neurological toxicity and coma).
Exposure-related factors Intravenous (IV) administration poses a higher risk of renal failure compared to oral dosing.
Population-specific notes Elderly patients and those with impaired renal function face an increased risk of neurological side effects.
Emergency-response actions Patients must be observed closely for signs of toxicity. Haemodialysis is documented as a measure to enhance drug removal.
When medical help is required Consult a physician or contact emergency services immediately if the suspected overdose leads to critical symptoms such as seizures or collapse.

Official Overdose Statements

Overdosage, particularly via the intravenous route, is officially documented to result in elevations of serum creatinine and blood urea nitrogen (BUN), potentially leading to acute renal failure. CNS toxicity manifestations, including confusion, hallucinations, and seizures, are listed in regulatory sources as documented outcomes of high systemic exposure. No specific antidote is known for Aciclovir overdose, and management focuses on symptomatic and supportive treatment.

Connection to the Overall Overdose Profile

Regulatory documents define the Aciclovir overdose profile by the severe risks of acute renal injury and CNS toxicity. The official guidance dictates that when severe manifestations occur, immediate medical attention must be sought. The procedural structure mandates close observation and the consideration of haemodialysis to manage symptoms and facilitate the removal of the drug from the system.

Therapeutic Uses of Aciclovir Generis

What Aciclovir Generis Treats: Main Uses and Benefits

Aciclovir Generis provides supportive therapeutic relief for conditions arising from the Herpes Simplex Virus (HSV) and the Varicella Zoster Virus (VZV), focusing on managing symptom severity and easing patient distress across various clinical contexts. This medication is commonly used to help with discomfort and support the healing of sores associated with these viral infections.

Key Therapeutic Applications

For patients managing these conditions, the medication is commonly used to address symptom clusters that include pain, burning, itching, and the visible manifestations of blisters and sores. By assisting with the healing process, it contributes to comfort during acute symptomatic phases. For recurrent, disruptive episodes, it is relevant in contexts where long-term symptomatic support is appropriate, and may be part of symptomatic management to help with outbreak frequency.

Quick Fact: Relief for Viral Pain and Lesions
Therapeutic Focus Managing acute lesions and nerve discomfort from HSV and VZV.
Core Benefit Supports the healing process and may assist with easing the overall symptom load.
Clinical Context Used in situations involving episodic or fluctuating manifestations, often during phases of increased distress.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Aciclovir Generis?

The population eligibility for Aciclovir is strictly defined by regulatory authorities, classifying users into permitted, restricted, and contraindicated groups.

Contraindications (Must Not Use)

Aciclovir is absolutely contraindicated in patients with a known hypersensitivity to the active substance, aciclovir, or its prodrug, valaciclovir. Patients diagnosed with rare hereditary metabolic disorders, such as glucose-galactose malabsorption or Lapp lactase deficiency, are typically advised not to use the oral tablet formulation.

Populations Requiring Conditional Use

Use is restricted and conditional in patients with impaired renal function because the drug is primarily eliminated by the kidneys. This requires a specific dose reduction to ensure safe use. Older adults also necessitate consideration for dose adjustment due to the likelihood of reduced renal function in this population. Both renal patients and older adults require close monitoring.

Age and Life Stage Eligibility

Aciclovir use is established in adults and children, though specific dosing varies by age group. Use during pregnancy is advised only if the potential benefits outweigh the unknown risks. The drug is excreted into breast milk, requiring caution during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Aciclovir is primarily eliminated from the body unchanged via the kidneys through a process involving active renal tubular secretion. Concomitant use with other medicinal products can affect this elimination pathway, altering aciclovir’s concentration in the body.

Drugs that compete with or inhibit renal tubular secretion, such as probenecid (used for gout) and cimetidine (used for stomach ulcers), are known to increase the systemic exposure (Area Under the Curve or AUC) and decrease the renal clearance of aciclovir. This pharmacokinetic interaction necessitates caution.

Another significant concern is the co-administration of aciclovir with other nephrotoxic medicinal products, as this combination increases the overall risk of renal impairment (kidney damage).

Specific medicine interactions include:

  • Mycophenolate Mofetil: Concurrent use with aciclovir or its prodrug (valaciclovir) has resulted in an increase in the plasma concentration of both aciclovir and the inactive metabolite of mycophenolate mofetil.
  • Zidovudine: Reports have associated this combination with an increased incidence of neurotoxicity (central nervous system adverse effects) and severe fatigue.
  • Theophylline/Aminophylline: Aciclovir may increase the serum levels of theophylline, a medicine for asthma, potentially leading to signs of toxicity.

Elderly patients or those with existing reduced kidney function may be at higher risk for central nervous system-related side effects when aciclovir is combined with other drugs that affect its elimination.

Mechanism of Action

Aciclovir is a synthetic purine nucleoside analogue whose action is mediated by high selectivity through a specific interference with the reproductive cycle of herpes viruses.


Targeted Prodrug Activation by Viral Enzymes

The molecule's action is initiated by selective activation, a mechanism dependent on the viral-encoded enzyme, thymidine kinase. This enzyme, found almost exclusively in virus-infected cells, performs the first phosphorylation step, converting the inactive Aciclovir molecule into its initial monophosphate form. This process ensures the drug is primarily activated only where the virus is actively replicating, resulting in the accumulation of the active molecule, Aciclovir triphosphate (ACV-TP), at the target site.


Obligate Chain Termination of Viral DNA Synthesis

The activated ACV-TP acts on the viral DNA polymerase, the enzyme responsible for synthesizing the virus’s genetic code. ACV-TP is both a competitive inhibitor and, critically, a fraudulent substrate that is incorporated into the growing viral DNA strand. Because the molecule lacks the chemical components needed for further attachment, its insertion results in obligate DNA chain termination. This modification of the viral genome synthesis pathway prevents the formation of new, functional viral particles, which establishes a physiological constraint on the viral multiplication process.

Dosage and Administration Information

The official use of Aciclovir Generis is governed by the chosen administration route, which includes oral (tablets/suspension), topical (cream/ointment), and intravenous (IV) infusion.

For oral therapy, the medication may be administered with or without food and should be taken with sufficient water to maintain adequate hydration. The treatment course requires strict adherence to the frequency pattern: acute episodes often use a divided daily dose, such as five times daily, while suppressive regimens typically utilize a twice-daily schedule. Official dosing must be initiated as early as possible—ideally at the first sign of symptoms—to align with labeled recommendations. If a dose is missed, the instruction is to take it as soon as it is remembered, but to skip the missed dose if it is almost time for the next scheduled dose, thereby avoiding a doubled quantity.

The IV route is reserved for severe or systemic infections. Intravenous doses are calculated based on the patient's body weight and must be administered by slow infusion over a period of at least one hour to minimize procedural risks. A critical official instruction is the requirement for dose reduction in populations with impaired renal function, including older adults, as Aciclovir is primarily eliminated through the kidneys.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aciclovir Generis

Evidence for Exploring Acute Herpes Simplex Virus (HSV) Infections

The research examined initial outbreaks of genital herpes and recurrent episodes primarily relied on short-term Randomized Controlled Trials (RCTs). These studies focused on immunocompetent adults and adolescents. Researchers examined outcomes related to physical discomfort, such as the time measured for lesion resolution and the duration of reported pain.

The findings describe patterns observed in these studies, where researchers monitored the time course of the initial viral episode. For recurrent episodes, research explored short-term symptom changes, providing insight into episodic or acute changes. Follow-up durations were limited, primarily concentrating on immediate recovery, and there is limited information for characterizing very long-term recurrence patterns that may occur following the treatment phase.


Evidence for Exploring Varicella Zoster Virus (VZV) Infections

Aciclovir Generis was studied in the context of exploring both shingles (Herpes Zoster) and chickenpox (Varicella) through controlled trials involving immunocompetent adults, older adults, and pediatric patients. Studies monitored outcomes related to physical discomfort and systemic imbalance, such as the time until new lesion formation ceased and the incidence of Post-Herpetic Neuralgia (PHN).

Research describes patterns observed related to the time course of both shingles and chickenpox. For chickenpox, findings indicate that measured outcomes are sensitive to the timing of treatment initiation. Studies focusing on PHN, a long-term outcome, note limitations regarding PHN outcomes and show that the evidence quality varies across studies.


Evidence for Preventing Recurrence (Suppressive Therapy)

The research examining the use of this compound to manage frequent recurrent genital herpes is based on extended-duration Randomized Controlled Trials and Observational Studies. These studies focused on adults with frequent recurrences, monitoring the frequency of recurrent episodes and the rate of asymptomatic viral shedding over extended periods. Data show patterns related to the incidence rate of outbreaks during continuous observation.

What remains uncertain is the influence of patient adherence, which is a necessary consideration. There is also limited information for long-term outcomes and comparative evidence is lacking against some newer antiviral options. Furthermore, research examined the use of the medicine in immunocompromised groups, but data for certain groups remain insufficient.

Key Studies & References

  1. Acyclovir: MedlinePlus Drug Information
  2. NICE Guideline: Clinical management of primary and recurrent genital herpes

Frequently Asked Questions (FAQ)

Common questions about Aciclovir Generis (FAQ)


Q: Can Aciclovir Generis be used during pregnancy according to official documents?

A: Official information describes that aciclovir is not known to be harmful when used during pregnancy. Regulatory agencies typically advise its use only when the potential benefit is considered to outweigh the possible risks to the foetus, and use is typically overseen by a healthcare professional.


Q: What is the official guidance on using Aciclovir Generis during breastfeeding?

A: According to official guidance, aciclovir is known to pass into breast milk in small amounts. Its use is generally considered acceptable if the baby is healthy, but caution is advised, and use is typically determined after consultation with a healthcare professional.


Q: What happens to the body if someone takes Aciclovir Generis for a long time?

A: Research has examined long-term use for suppressive therapy, focusing on the reduction of outbreak frequency. Long-term safety data in official documents notes that serious, though reversible, neurological effects are typically reported in patients with pre-existing conditions or high doses, not solely as a consequence of extended use in otherwise healthy people.


Q: Does Aciclovir Generis affect the immune system in a major way?

A: Aciclovir is an antiviral medication that works by selectively targeting and interfering with viral DNA synthesis. It is not generally classified as a broad immune suppressant. Its action is highly specific to the herpes group of viruses it is designed to manage.


Q: What are the most serious, though rare, side effects described for Aciclovir Generis?

A: Regulatory documents list very rare, but serious, side effects. These can include acute kidney failure, changes in blood counts (such as anemia), and neurological issues like seizures, agitation, and confusion. A severe allergic reaction, such as swelling or difficulty breathing, necessitates immediate medical attention.


Q: Can Aciclovir Generis be used by people who have kidney problems?

A: Use in people with impaired renal (kidney) function is conditional and requires caution. Because the drug is primarily cleared by the kidneys, official regulatory information mandates that the dose must be specifically adjusted. Furthermore, adequate hydration is specified as necessary to support safe use.


Q: Can individuals with liver conditions use Aciclovir Generis?

A: Official labeling mentions that rare side effects include reversible rises in liver enzymes, and very rare cases of serious liver issues like hepatitis or jaundice have been reported. While a dose adjustment is not required for liver function in the same way it is for kidney function, careful monitoring is generally advised for all patients.


Q: What is the risk of resistance developing when using Aciclovir Generis?

A: Regulatory documents state that prolonged or repeated use in severely immunocompromised individuals may result in the selection of virus strains with reduced sensitivity (resistance). This occurs when the virus alters its necessary thymidine kinase (TK) enzyme, making the drug less effective.


Q: Are there any known interactions between Aciclovir Generis and common pain relievers?

A: Regulatory-aligned consumer information indicates that common pain relievers like paracetamol are generally considered compatible with aciclovir. However, due to the complexity of all potential drug combinations and individual health status, patients are generally advised to discuss all potential drug combinations with a healthcare provider.


Q: Does using Aciclovir Generis affect the reliability of oral contraceptives?

A: No direct pharmacokinetic interaction is typically listed between aciclovir and most combined oral contraceptives. However, official information notes that severe gastrointestinal side effects (like vomiting or diarrhea), which are listed as common side effects of aciclovir, may potentially affect the absorption and reliability of oral contraceptives. Patients with concerns about reliability are typically advised to seek guidance from a doctor.


Q: What is the main difference between Aciclovir Generis and other antiviral medicines I've seen?

A: Aciclovir is classified as a purine nucleoside analogue with a highly selective action. This means it is designed to target specific viral enzymes, primarily in the herpes family. This mechanism differs from other classes of antivirals (e.g., those for influenza or HIV) which target different viral processes and are used for different types of infections.


Q: How quickly can someone typically expect Aciclovir Generis to start working?

A: Official research and information focus on outcomes such as the measured time for new lesion formation to cease or the duration of reported pain. These findings indicate that the clinical response is highly sensitive to the timing of treatment initiation, with studies showing better outcomes when the medication is started at the earliest sign of symptoms.


Q: Do studies suggest Aciclovir Generis prevents future outbreaks?

A: Official information and research support the use of aciclovir for suppression (prevention of recurrences) of recurrent herpes simplex infections. The goal of suppressive therapy is specifically to reduce the frequency and severity of recurrent episodes over an extended observation period.


Q: What happens if someone accidentally uses Aciclovir Generis for a bacterial infection?

A: Aciclovir is an antiviral agent whose mechanism of action relies on activation by specific viral enzymes. It is not classified as an antibiotic and therefore is not expected to have any effect on bacterial infections.


Q: Is there a specific period of time that Aciclovir Generis is typically used for?

A: The duration of use is typically determined by the type of infection being managed. Acute episodes of herpes are often treated for a short, defined period. Suppressive therapy for managing frequent recurrences involves continuous use over extended periods, which is reviewed regularly by a healthcare professional.


Q: What is the purpose of the prophylaxis use of Aciclovir Generis?

A: Prophylaxis is the use of a medicine to prevent an infection from occurring. Aciclovir is officially indicated for the prophylaxis of herpes simplex infections in certain groups, such as those who are immunocompromised and at high risk of a serious primary infection or reactivation.


Q: Is Aciclovir Generis generally considered a prescription-only medicine?

A: The oral tablet and intravenous forms of aciclovir are generally classified as Prescription Only Medicine (POM) in most international regulatory jurisdictions. Certain low-strength topical cream formulations may be available without a prescription, depending on the country’s local regulations.


Q: Does official sources list a need for blood tests while using Aciclovir Generis?

A: Routine blood tests are not generally mentioned for all users. However, official documents note that the drug can rarely cause changes in blood counts (like anemia). Monitoring of aciclovir plasma levels may be considered in patients with renal dysfunction to check for drug accumulation.


Q: Is Aciclovir Generis known to cause changes in sleep patterns?

A: The list of very rare neurological side effects includes somnolence (drowsiness) and agitation, which may indirectly influence a person’s sleep patterns. These neurological effects are most often reported in patients who have pre-existing kidney issues or who are receiving high doses.


Q: Are there different strengths of Aciclovir Generis available?

A: Yes, Aciclovir is available in multiple strengths for oral use, such as 200 mg, 400 mg, and 800 mg tablets, to align with the different treatment requirements for acute, suppressive, or Varicella Zoster infections.


Q: Does the medicine come in a liquid or suspension form for people who cannot swallow pills?

A: Yes, in addition to tablets, Aciclovir is available in an oral suspension or liquid form. This preparation is an option that can be used by patients, especially children or those who have difficulty swallowing pills.


Q: Is it common for people to continue having symptoms even after using Aciclovir Generis?

A: Aciclovir is a viral management drug that lessens the severity and shortens the duration of an outbreak by interfering with viral multiplication. It does not cure the underlying viral infection. It is not uncommon for symptoms to improve but not entirely resolve during the treatment course, and the virus remains dormant in the body.


Q: Is Aciclovir Generis related to any type of antibiotic?

A: No, Aciclovir is classified as an antiviral drug (specifically a purine nucleoside analogue) and belongs to a different pharmacological class than antibiotics, which are used to target bacterial infections. It is effective only against specific viruses.


Q: Does the effectiveness of Aciclovir Generis vary by age or weight?

A: While the core antiviral effectiveness is consistent, the dosing of intravenous forms and doses for children are calculated based on body weight. Furthermore, the clearance of the drug varies significantly with age, particularly in older adults due to potential changes in kidney function, which influences how the drug is processed.


Q: Are there any warnings about using Aciclovir Generis with alcohol?

A: Official patient information often states that alcohol does not interfere with the drug’s antiviral properties. However, alcohol consumption may potentially worsen some common side effects of aciclovir, such as dizziness or headache, and may increase the risk of dehydration.


Q: Is it necessary to drink extra water while using Aciclovir Generis?

A: Official regulatory warnings specify that care should be taken to maintain adequate hydration, especially for patients receiving high oral doses. This is specified as important to help the kidneys process the medicine and minimize the rare risk of crystallization or kidney problems.

How should Aciclovir Generis be stored and disposed of?

How to Store and Dispose of Aciclovir Generis

Storage of Aciclovir tablets must follow the specific conditions defined in official regulatory labeling to ensure product integrity.

Official Storage Requirements

  • Temperature and Handling: The tablets must be stored within a specific temperature range, often below 25 C or 30 C, and must not be frozen. Some labeling specifies storage between 15 C and 25 C.
  • Protection: It is mandatory to protect the tablets from light and moisture. To achieve this, the product must be stored in its original package and the container should be kept tightly closed.
  • Child Safety: As with all medications, the tablets must be kept out of the sight and reach of children.

Official Disposal Instructions

Unused or expired tablets must be handled as pharmaceutical waste. Official instructions state that the medicine must be disposed of in accordance with local requirements and explicitly prohibit disposal via wastewater or regular household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aciclovir Generis found in:

A-Z Index: